Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer

PHASE3UnknownINTERVENTIONAL
Enrollment

1,108

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

recombinant human endostatin

recombinant human endostatin 15mg per ampul for injection 7.5mg/m2 IV (in the vein) on 1st to 14th days of a 21- day cycle, totally 4 cycles are needed

Trial Locations (1)

100021

RECRUITING

The Lung Cancer Center of Cancer Hospital, Beijing

Sponsors
All Listed Sponsors
collaborator

Chinese Academy of Medical Sciences

OTHER

collaborator

Shanghai Jiao Tong University School of Medicine

OTHER

collaborator

Beijing Chao Yang Hospital

OTHER

lead

Chinese Academy of Sciences

OTHER_GOV

NCT00576914 - Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter